Episurf Medical achieved a milestone of 100 accounts approved and connected to the company's proprietary μifidelity™ IT platform, used with Episealer® personalized implants and Epiguide® drill guides to treat localized joint cartilage injury.
μiFidelity is designed to support implants that may be cost-efficiently tailored to individual injuries for optimal fit with minimal intervention.
During 2016, the company will continue activities to expand sales in Germany and the U.K.
Source: Episurf Medical AB
Episurf's first product, Episealer® Femoral Condyle, received CE Mark approval in 3Q13, and sales subsidiaries were established in 2Q15. For 3Q15, the company reported sales of SEK 150,174 (~US $17,380), +91.9% vs. 3Q14, and YTD 2015 sales of SEK 641,094 (~$74,200), +441% vs. the prior year.